226 related articles for article (PubMed ID: 26568036)
1. Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.
Irving JA
Br J Haematol; 2016 Mar; 172(5):655-66. PubMed ID: 26568036
[TBL] [Abstract][Full Text] [Related]
2. Relapsed childhood acute lymphoblastic leukaemia.
Bhojwani D; Pui CH
Lancet Oncol; 2013 May; 14(6):e205-17. PubMed ID: 23639321
[TBL] [Abstract][Full Text] [Related]
3. Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches.
Locatelli F; Moretta F; Rutella S
Curr Opin Oncol; 2013 Nov; 25(6):707-15. PubMed ID: 24076579
[TBL] [Abstract][Full Text] [Related]
4. The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure.
Beesley AH; Cummings AJ; Freitas JR; Hoffmann K; Firth MJ; Ford J; de Klerk NH; Kees UR
Br J Haematol; 2005 Nov; 131(4):447-56. PubMed ID: 16281934
[TBL] [Abstract][Full Text] [Related]
5. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
Pierro J; Hogan LE; Bhatla T; Carroll WL
Expert Rev Anticancer Ther; 2017 Aug; 17(8):725-736. PubMed ID: 28649891
[TBL] [Abstract][Full Text] [Related]
6. Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.
Chen C; Bartenhagen C; Gombert M; Okpanyi V; Binder V; Röttgers S; Bradtke J; Teigler-Schlegel A; Harbott J; Ginzel S; Thiele R; Husemann P; Krell PF; Borkhardt A; Dugas M; Hu J; Fischer U
Leuk Res; 2015 Sep; 39(9):990-1001. PubMed ID: 26189108
[TBL] [Abstract][Full Text] [Related]
7. Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.
Lee-Sherick AB; Linger RM; Gore L; Keating AK; Graham DK
Br J Haematol; 2010 Nov; 151(4):295-311. PubMed ID: 20813012
[TBL] [Abstract][Full Text] [Related]
8. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.
Tasian SK; Hunger SP
Br J Haematol; 2017 Mar; 176(6):867-882. PubMed ID: 27984637
[TBL] [Abstract][Full Text] [Related]
9. Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia.
Yan J; Jiang N; Huang G; Tay JL; Lin B; Bi C; Koh GS; Li Z; Tan J; Chung TH; Lu Y; Ariffin H; Kham SK; Yeoh AE; Chng WJ
Br J Haematol; 2013 Oct; 163(1):93-103. PubMed ID: 23888996
[TBL] [Abstract][Full Text] [Related]
10. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL.
Han BW; Feng DD; Li ZG; Luo XQ; Zhang H; Li XJ; Zhang XJ; Zheng LL; Zeng CW; Lin KY; Zhang P; Xu L; Chen YQ
Hum Mol Genet; 2011 Dec; 20(24):4903-15. PubMed ID: 21926415
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia.
Bhadri VA; Trahair TN; Lock RB
J Paediatr Child Health; 2012 Aug; 48(8):634-40. PubMed ID: 22050419
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
Kaspers GJ; Wijnands JJ; Hartmann R; Huismans L; Loonen AH; Stackelberg A; Henze G; Pieters R; Hählen K; Van Wering ER; Veerman AJ
Eur J Cancer; 2005 Jun; 41(9):1300-3. PubMed ID: 15869873
[TBL] [Abstract][Full Text] [Related]
13. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.
Mullighan CG
Clin Cancer Res; 2011 Feb; 17(3):396-400. PubMed ID: 21149616
[TBL] [Abstract][Full Text] [Related]
14. CREBBP mutations in relapsed acute lymphoblastic leukaemia.
Mullighan CG; Zhang J; Kasper LH; Lerach S; Payne-Turner D; Phillips LA; Heatley SL; Holmfeldt L; Collins-Underwood JR; Ma J; Buetow KH; Pui CH; Baker SD; Brindle PK; Downing JR
Nature; 2011 Mar; 471(7337):235-9. PubMed ID: 21390130
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.
Spijkers-Hagelstein JA; Schneider P; Pinhanços SM; Garrido Castro P; Pieters R; Stam RW
Eur J Cancer; 2014 Jun; 50(9):1665-74. PubMed ID: 24703900
[TBL] [Abstract][Full Text] [Related]
16. Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia.
Estrov Z; Ouspenskaia MV; Felix EA; McClain KL; Lee MS; Harris D; Pinkel DP; Zipf TF
Leukemia; 1994 Jan; 8(1):46-52. PubMed ID: 8289497
[TBL] [Abstract][Full Text] [Related]
17. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
18. Substance P--a potent risk factor in childhood lymphoblastic leukaemia.
Nowicki M; Miśkowiak B
Leukemia; 2003 Jun; 17(6):1096-9. PubMed ID: 12764374
[TBL] [Abstract][Full Text] [Related]
19. Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.
Brivio E; Baruchel A; Beishuizen A; Bourquin JP; Brown PA; Cooper T; Gore L; Kolb EA; Locatelli F; Maude SL; Mussai FJ; Vormoor-Bürger B; Vormoor J; von Stackelberg A; Zwaan CM
Eur J Cancer; 2022 Mar; 164():1-17. PubMed ID: 35121370
[TBL] [Abstract][Full Text] [Related]
20. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
Mar BG; Bullinger LB; McLean KM; Grauman PV; Harris MH; Stevenson K; Neuberg DS; Sinha AU; Sallan SE; Silverman LB; Kung AL; Lo Nigro L; Ebert BL; Armstrong SA
Nat Commun; 2014 Mar; 5():3469. PubMed ID: 24662245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
